Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.2 USD -4.16% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Revenue
$652m
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
25%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%

Supernus Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Supernus Pharmaceuticals Inc

Not Available

Breakdown by Segments
Supernus Pharmaceuticals Inc

Total Revenue: 607.5m USD
100%
Product: 573.9m USD
94.5%
Qelbree: 140.2m USD
23.1%
Gocovri: 119.6m USD
19.7%
Oxtellar X R: 113.4m USD
18.7%
Trokendi Xr: 94.3m USD
15.5%
Apokyn: 75.1m USD
12.4%
Royalty: 33.6m USD
5.5%
Manufactured Product, Other: 31.3m USD
5.1%
Show More
Show Less

See Also

What is Supernus Pharmaceuticals Inc's Revenue?
Revenue
652m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Revenue amounts to 652m USD.

What is Supernus Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
25%

Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Supernus Pharmaceuticals Inc have been 5% over the past three years , 10% over the past five years , and 25% over the past ten years .

Back to Top